Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01464177 : Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- 18 years of age or older

- KPS equal or greater than 60

- Anatomopathological confirmation of GBM

- Previous RT with therapeutic doses

- At least 5 months from the end of RT course

- Not a candidate to surgical resection

- Patients with partial resection after resection of recurrent GBM will be allowed

- Patients with local progression after resection of recurrent GBM will be allowed

- Lesion with a maximal 150cc volume, as defined by enhancing portion in contrast
enhanced MRI

- Hemoglobin levels (Hb) equal or greater than 10ng/dl. Blood transfusions to correct
the Hb will be allowed.

Exclusion Criteria:

- Important comorbidities

- Concomitant chemotherapy

- Contraindication to MRI

- Brainstem glioma
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01464177      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740